New combo therapy targets aggressive lung cancer transformation

This phase 2 trial tests a combination of tarlatamab (a targeted immune therapy), chemotherapy, and atezolizumab in 50 adults whose lung cancer has transformed from a common type (adenocarcinoma) to a more aggressive small cell form after initial treatment. The goal is to see if this approach can improve how long people live without their cancer growing. Participants must have a specific EGFR mutation and no prior treatment for the transformed cancer.